Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Phase I, Open-label, Single-center Proof of Concept Study Designed to Test the Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in Combination With CDX-301 in Subjects With a History of Prostate Cancer, in the Adjuvant Setting

Next Previous
X
Search
Trial Profile

Phase I, Open-label, Single-center Proof of Concept Study Designed to Test the Safety and Tolerability of PGV001-based Personalized Multi-peptide Vaccines in Combination With CDX-301 in Subjects With a History of Prostate Cancer, in the Adjuvant Setting

Status: Recruiting
Phase of Trial: Phase I

Latest Information Update: 24 Oct 2023

Price : $35 *
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs CDX 301 (Primary) ; Peptide vaccines (Primary) ; Poly ICLC (Primary)
  • Indications Adenocarcinoma; Prostate cancer
  • Focus Adverse reactions; Proof of concept

    • Most Recent Events

    • 18 Oct 2023 Planned End Date changed from 1 Dec 2027 to 1 Jan 2028.
    • 18 Oct 2023 Planned primary completion date changed from 1 Dec 2026 to 1 Jan 2027.
    • 08 Sep 2022 Planned End Date changed from 1 Dec 2031 to 1 Dec 2027.

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top